4D Molecular Therapeutics’ $193.2 Million Initial Public Offering

Ambrogio Visconti

Latham & Watkins LLP advised 4D Molecular Therapeutics on the deal. 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here